Autoimmune hepatitis: A comprehensive review

Journal of Autoimmunity

Volumn 41, Issue , 2013, Pages 126-139

  Liberal, Rodrigo ^a,b   Grant, Charlotte R ^a   Mieli Vergani, Giorgina ^a   Vergani, Diego ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b University of Porto   (Portugal)

Author keywords

Autoimmune hepatitis; Immunogenetics; Liver transplantation; Overlap syndromes; Regulatory T cells; Treatment

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BUDESONIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LIVER ENZYME; METHOTREXATE; MITOCHONDRION ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; SMOOTH MUSCLE ANTIBODY; SOLUBLE CD4 ANTIGEN; TACROLIMUS;

AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; FULMINANT HEPATIC FAILURE; GENETIC SUSCEPTIBILITY; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER CYTOSOL; LIVER INJURY; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MOLECULAR MIMICRY; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

AUTOANTIBODIES; FEMALE; HEPATITIS, AUTOIMMUNE; HLA-DRB1 CHAINS; HUMANS; LIVER; MODELS, IMMUNOLOGICAL;

EID: 84875912781     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.11.002     Document Type: Review

References (150)

1. Leber Waldenström J. Blutprotein und Nahrungseiweiss. Deutsch Gesellshaff Z Verdan Stoffwechselkr 1950, 15:113-119.
2. Mackay I.R., Cowling D.C., Taft L.I. Lupoid hepatitis. Lancet 1956, 271:1323-1326.
3. Cook G.C., Mulligan R., Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971, 40:159-185.
4. Soloway R.D., Summerskill W.H., Baggenstoss A.H., Geall M.G., Gitnick G.L., Elveback I.R., et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972, 63:820-833.
5. Murray-Lyon I.M., Stern R.B., Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973, 1:735-737.
6. Gurian L.E., Rogoff T.M., Ware A.J., Jordan R.E., Combes B., Gilliam J.N. The immunologic diagnosis of chronic active "autoimmune" hepatitis: distinction from systemic lupus erythematosus. Hepatology 1985, 5:397-402.
7. Johnson P.J., McFarlane I.G. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993, 18:998-1005.
8. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
9. Hennes E.M., Zeniya M., Czaja A.J., Pares A., Dalekos G.N., Krawitt E.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
10. Vergani D., Longhi M.S., Bogdanos D.P., Ma Y., Mieli-Vergani G. Autoimmune hepatitis. Semin Immunopathol 2009, 31:421-435.
11. Boberg K.M., Aadland E., Jahnsen J., Raknerud N., Stiris M., Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33:99-103.
12. Primo J., Merino C., Fernandez J., Moles J.R., Llorca P., Hinojosa J. Incidence and prevalence of autoimmune hepatitis in the area of the Hospital de Sagunto (Spain). Gastroenterol Hepatol 2004, 27:239-243.
13. Hurlburt K.J., McMahon B.J., Deubner H., Hsu-Trawinski B., Williams J.L., Kowdley K.V. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002, 97:2402-2407.
14. Whalley S., Puvanachandra P., Desai A., Kennedy H. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med 2007, 7:119-124.
15. Ngu J.H., Bechly K., Chapman B.A., Burt M.J., Barclay M.L., Gearry R.B., et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women?. J Gastroenterol Hepatol 2010, 25:1681-1686.
16. Toda G., Zeniya M., Watanabe F., Imawari M., Kiyosawa K., Nishioka M., et al. Present status of autoimmune hepatitis in Japan-correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol 1997, 26:1207-1212.
17. Lam K.C., Lai C.L., Wu P.C., Todd D. Etiological spectrum of liver cirrhosis in the Chinese. J Chronic Dis 1980, 33:375-381.
18. Qiu D., Wang Q., Wang H., Xie Q., Zang G., Jiang H., et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol 2011, 54:340-347.
19. Manns M.P., Czaja A.J., Gorham J.D., Krawitt E.L., Mieli-Vergani G., Vergani D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010, 51:2193-2213.
20. Al-Chalabi T., Boccato S., Portmann B.C., McFarlane I.G., Heneghan M.A. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006, 45:575-583.
21. Longhi M.S., Mitry R.R., Samyn M., Scalori A., Hussain M.J., Quaglia A., et al. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology 2009, 50:130-142.
22. Djilali-Saiah I., Fakhfakh A., Louafi H., Caillat-Zucman S., Debray D., Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol 2006, 45:844-850.
23. Agarwal K., Czaja A.J., Jones D.E., Donaldson P.T. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000, 31:49-53.
24. Cookson S., Constantini P.K., Clare M., Underhill J.A., Bernal W., Czaja A.J., et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999, 30:851-856.
25. Agarwal K., Czaja A.J., Donaldson P.T. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens 2007, 69:227-235.
26. Kerkar N., Choudhuri K., Ma Y., Mahmoud A., Bogdanos D.P., Muratori L., et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003, 170:1481-1489.
27. Bogdanos D.P., Choudhuri K., Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001, 21:225-232.
28. Bjornsson E., Talwalkar J., Treeprasertsuk S., Kamath P.S., Takahashi N., Sanderson S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010, 51:2040-2048.
29. Crispe I.N. Liver antigen-presenting cells. J Hepatol 2011, 54:357-365.
30. Ebrahimkhani M.R., Mohar I., Crispe I.N. Cross-presentation of antigen by diverse subsets of murine liver cells. Hepatology 2011, 54:1379-1387.
31. Ichiki Y., Aoki C.A., Bowlus C.L., Shimoda S., Ishibashi H., Gershwin M.E. T cell immunity in autoimmune hepatitis. Autoimmun Rev 2005, 4:315-321.
32. Lobo-Yeo A., Senaldi G., Portmann B., Mowat A.P., Mieli-Vergani G., Vergani D. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology 1990, 12:224-232.
33. Senaldi G., Lobo-Yeo A., Mowat A.P., Mieli-Vergani G., Vergani D. Class I and class II major histocompatibility complex antigens on hepatocytes: importance of the method of detection and expression in histologically normal and diseased livers. J Clin Pathol 1991, 44:107-114.
34. Delneste Y., Charbonnier P., Herbault N., Magistrelli G., Caron G., Bonnefoy J.Y., et al. Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages. Blood 2003, 101:143-150.
35. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004, 75:163-189.
36. Longhi M.S., Ma Y., Mieli-Vergani G., Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun 2010, 34:7-14.
37. Jensen D.M., McFarlane I.G., Portmann B.S., Eddleston A.L., Williams R. Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med 1978, 299:1-7.
38. McFarlane B.M., McSorley C.G., Vergani D., McFarlane I.G., Williams R. Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol 1986, 3:196-205.
39. Zhao L., Tang Y., You Z., Wang Q., Liang S., Han X., et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One 2011, 6:e18909.
40. Harada K., Shimoda S., Sato Y., Isse K., Ikeda H., Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 2009, 157:261-270.
41. Wen L., Peakman M., Mieli-Vergani G., Vergani D. Elevation of activated gamma delta T cell receptor bearing T lymphocytes in patients with autoimmune chronic liver disease. Clin Exp Immunol 1992, 89:78-82.
42. Ferri S., Longhi M.S., De Molo C., Lalanne C., Muratori P., Granito A., et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology 2010, 52:999-1007.
43. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
44. Hodgson H.J., Wands J.R., Isselbacher K.J. Alteration in suppressor cell activity in chronic active hepatitis. Proc Natl Acad Sci U S A 1978, 75:1549-1553.
45. Nouri-Aria K.T., Hegarty J.E., Alexander G.J., Eddleston A.L., Williams R. Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. N Engl J Med 1982, 307:1301-1304.
46. Vento S., Hegarty J.E., Bottazzo G., Macchia E., Williams R., Eddleston A.L. Antigen specific suppressor cell function in autoimmune chronic active hepatitis. Lancet 1984, 1:1200-1204.
47. Longhi M.S., Ma Y., Bogdanos D.P., Cheeseman P., Mieli-Vergani G., Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004, 41:31-37.
48. Longhi M.S., Ma Y., Mitry R.R., Bogdanos D.P., Heneghan M., Cheeseman P., et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 2005, 25:63-71.
49. Peiseler M., Sebode M., Franke B., Wortmann F., Schwinge D., Quaas A., et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol 2012.
50. Longhi M.S., Ma Y., Mieli-Vergani G., Vergani D. Regulatory T cells in autoimmune hepatitis. J Hepatol 2012.
51. Oo Y.H., Adams D.H. Regulatory T cells and autoimmune hepatitis: defective cells or a hostile environment?. J Hepatol 2012.
52. Mueller D.L. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010, 11:21-27.
53. Liberal R., Grant C.R., Holder B., Ma Y., Mieli-Vergani G., Vergani D., et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective Galectin-9/Tim-3 pathway. Hepatology 2012.
54. Lapierre P., Beland K., Martin C., Alvarez F., Alvarez F. Forkhead box p3+ regulatory T cell underlies male resistance to experimental type 2 autoimmune hepatitis. Hepatology 2010, 51:1789-1798.
55. Holdener M., Hintermann E., Bayer M., Rhode A., Rodrigo E., Hintereder G., et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008, 205:1409-1422.
56. Kido M., Watanabe N., Okazaki T., Akamatsu T., Tanaka J., Saga K., et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology 2008, 135:1333-1343.
57. Gregorio G.V., Portmann B., Reid F., Donaldson P.T., Doherty D.G., McCartney M., et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997, 25:541-547.
58. Feld J.J., Dinh H., Arenovich T., Marcus V.A., Wanless I.R., Heathcote E.J. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005, 42:53-62.
59. Crapper R.M., Bhathal P.S., Mackay I.R., Frazer I.H. 'Acute' autoimmune hepatitis. Digestion 1986, 34:216-225.
60. Kessler W.R., Cummings O.W., Eckert G., Chalasani N., Lumeng L., Kwo P.Y. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004, 2:625-631.
61. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 2006, 354:54-66.
62. Kogan J., Safadi R., Ashur Y., Shouval D., Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002, 35:75-81.
63. Czaja A.J., Carpenter H.A. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004, 40:646-652.
64. Roberts S.K., Therneau T.M., Czaja A.J. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996, 110:848-857.
65. Schramm C., Herkel J., Beuers U., Kanzler S., Galle P.R., Lohse A.W. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006, 101:556-560.
66. Heneghan M.A., Norris S.M., O'Grady J.G., Harrison P.M., McFarlane I.G. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001, 48:97-102.
67. Werner M., Prytz H., Ohlsson B., Almer S., Bjornsson E., Bergquist A., et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008, 43:1232-1240.
68. Muratori P., Granito A., Quarneti C., Ferri S., Menichella R., Cassani F., et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009, 50:1210-1218.
69. Perdigoto R., Carpenter H.A., Czaja A.J. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992, 14:325-331.
70. Villalta D., Girolami D., Bidoli E., Bizzaro N., Tampoia M., Liguori M., et al. High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue tranglutaminase autoantibodies. J Clin Lab Anal 2005, 19:6-10.
71. Uthman I., Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology (Oxford) 2007, 46:1641-1647.
72. Quinet de Andrade L.V., Quinet de Andrade L., Fonseca Chebli J.M., Duarte Gaburri P. Autoimmune pancreatitis and hepatitis: an uncommon association. Am J Gastroenterol 2000, 95:2391-2394.
73. Sema K., Takei M., Uenogawa K., Horikoshi A., Hosokawa Y., Matsuda M., et al. Felty's syndrome with chronic hepatitis and compatible autoimmune hepatitis: a case presentation. Intern Med 2005, 44:335-341.
74. Paul K., Wille L., Feist D., Kayser K. Fibrosing alveolitis in a 7-year-old girl with autoimmune hemolytic anemia and autoimmune hepatitis. Pneumologie 1991, 45:928-931.
75. Yamaike N., Saigo K., Imoto S., Miyachi H., Morita S., Maeda Y., et al. Autoimmune hepatitis accompanied by idiopathic thrombocytopenic purpura and Sjogren's syndrome. Intern Med 2002, 41:72.
76. Luth S., Birklein F., Schramm C., Herkel J., Hennes E., Muller-Forell W., et al. Multiplex neuritis in a patient with autoimmune hepatitis: a case report. World J Gastroenterol 2006, 12:5396-5398.
77. Han Y.S., Kim B.H., Kim T.H., Dong S.H., Kim H.J., Chang Y.W., et al. Autoimmune hepatitis in a patient with myasthenia gravis and thymoma-a report on the first case in Korea. Korean J Intern Med 2000, 15:151-155.
78. Banerjee A.K., Grainger S.L., Davies D.R., Thompson R.P. Active chronic hepatitis and febrile panniculitis. Gut 1989, 30:1018-1019.
79. Michele T.M., Fleckenstein J., Sgrignoli A.R., Thuluvath P.J. Chronic active hepatitis in the type I polyglandular autoimmune syndrome. Postgrad Med J 1994, 70:128-131.
80. Ko K.F., Ho T., Chan K.W. Autoimmune chronic active hepatitis and polymyositis in a patient with myasthenia gravis and thymoma. J Neurol Neurosurg Psychiatry 1995, 59:558-559.
81. Romanelli R.G., La Villa G., Almerigogna F., Vizzutti F., Di Pietro E., Fedi V., et al. Uveitis in autoimmune hepatitis: a case report. World J Gastroenterol 2006, 12:1637-1640.
82. Sacher M., Blumel P., Thaler H., Manns M. Chronic active hepatitis associated with vitiligo, nail dystrophy, alopecia and a new variant of LKM antibodies. J Hepatol 1990, 10:364-369.
83. Yeoman A.D., Al-Chalabi T., Karani J.B., Quaglia A., Devlin J., Mieli-Vergani G., et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008, 48:863-870.
84. Vergani D., Alvarez F., Bianchi F.B., Cancado E.L., Mackay I.R., Manns M.P., et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004, 41:677-683.
85. Czaja A.J., Cassani F., Cataleta M., Valentini P., Bianchi F.B. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci 1997, 42:1688-1696.
86. Tan E.M., Feltkamp T.E., Smolen J.S., Butcher B., Dawkins R., Fritzler M.J., et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997, 40:1601-1611.
87. Hilario M.O., Len C.A., Roja S.C., Terreri M.T., Almeida G., Andrade L.E. Frequency of antinuclear antibodies in healthy children and adolescents. Clin Pediatr (Phila) 2004, 43:637-642.
88. Bogdanos D.P., Invernizzi P., Mackay I.R., Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008, 14:3374-3387.
89. Bottazzo G.F., Florin-Christensen A., Fairfax A., Swana G., Doniach D., Groeschel-Stewart U. Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol 1976, 29:403-410.
90. Muratori P., Muratori L., Agostinelli D., Pappas G., Veronesi L., Granito A., et al. Smooth muscle antibodies and type 1 autoimmune hepatitis. Autoimmunity 2002, 35:497-500.
91. Strassburg C.P., Manns M.P. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002, 22:339-352.
92. Rizzetto M., Swana G., Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 1973, 15:331-344.
93. Martini E., Abuaf N., Cavalli F., Durand V., Johanet C., Homberg J.C. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988, 8:1662-1666.
94. Abuaf N., Johanet C., Chretien P., Martini E., Soulier E., Laperche S., et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992, 16:892-898.
95. Lenzi M., Manotti P., Muratori L., Cataleta M., Ballardini G., Cassani F., et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 1995, 36:749-754.
96. Han S., Tredger M., Gregorio G.V., Mieli-Vergani G., Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 1995, 21:58-62.
97. Lapierre P., Hajoui O., Homberg J.C., Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999, 116:643-649.
98. Muratori L., Cataleta M., Muratori P., Lenzi M., Bianchi F.B. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998, 42:721-726.
99. Manns M., Gerken G., Kyriatsoulis A., Staritz M., Meyer zum Buschenfelde K.H. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987, 1:292-294.
100. Ma Y., Okamoto M., Thomas M.G., Bogdanos D.P., Lopes A.R., Portmann B., et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002, 35:658-664.
101. Costa M., Rodriguez-Sanchez J.L., Czaja A.J., Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin Exp Immunol 2000, 121:364-374.
102. Palioura S., Sherrer R.L., Steitz T.A., Soll D., Simonovic M. The human SepSecS-tRNASec complex reveals the mechanism of selenocysteine formation. Science 2009, 325:321-325.
103. Czaja A.J., Carpenter H.A. Histological findings in chronic hepatitis C with autoimmune features. Hepatology 1997, 26:459-466.
104. Stravitz R.T., Lefkowitch J.H., Fontana R.J., Gershwin M.E., Leung P.S., Sterling R.K., et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011, 53:517-526.
105. Gregorio G.V., Portmann B., Karani J., Harrison P., Donaldson P.T., Vergani D., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001, 33:544-553.
106. Czaja A., Carpenter H.A. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig Dis Sci 1996, 41:305-314.
107. Czaja A.J. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008, 48:1540-1548.
108. Muratori P., Granito A., Pappas G., Muratori L. Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology 2009, 49:1782-1783. author reply 3.
109. Yeoman A.D., Westbrook R.H., Al-Chalabi T., Carey I., Heaton N.D., Portmann B.C., et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009, 50:538-545.
110. Czaja A.J. The variant forms of autoimmune hepatitis. Ann Intern Med 1996, 125:588-598.
111. Beuers U., Rust C. Overlap syndromes. Semin Liver Dis 2005, 25:311-320.
112. Boberg K.M., Chapman R.W., Hirschfield G.M., Lohse A.W., Manns M.P., Schrumpf E. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011, 54:374-385.
113. Abdo A.A., Bain V.G., Kichian K., Lee S.S. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002, 36:1393-1399.
114. Vierling J.M. Primary biliary cirrhosis and autoimmune cholangiopathy. Clin Liver Dis 2004, 8:177-194.
115. Kloppel G., Seifert G., Lindner H., Dammermann R., Sack H.J., Berg P.A. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity. Virchows Arch A Pathol Anat Histol 1977, 373:143-160.
116. Chazouilleres O., Wendum D., Serfaty L., Montembault S., Rosmorduc O., Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28:296-301.
117. Poupon R., Chazouilleres O., Corpechot C., Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006, 44:85-90.
118. Lohse A.W., zum Buschenfelde K.H., Franz B., Kanzler S., Gerken G., Dienes H.P. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999, 29:1078-1084.
119. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267.
120. el-Shabrawi M., Wilkinson M.L., Portmann B., Mieli-Vergani G., Chong S.K., Williams R., et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987, 92:1226-1235.
121. Gohlke F., Lohse A.W., Dienes H.P., Lohr H., Marker-Hermann E., Gerken G., et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996, 24:699-705.
122. Floreani A., Rizzotto E.R., Ferrara F., Carderi I., Caroli D., Blasone L., et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005, 100:1516-1522.
123. Kaya M., Angulo P., Lindor K.D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000, 33:537-542.
124. Abdalian R., Dhar P., Jhaveri K., Haider M., Guindi M., Heathcote E.J. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008, 47:949-957.
125. Vergani D., Mieli-Vergani G. Pharmacological management of autoimmune hepatitis. Expert Opin Pharmacother 2011, 12:607-613.
126. Johnson P.J., McFarlane I.G., Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995, 333:958-963.
127. Krawitt E.L. Clinical features and management of autoimmune hepatitis. World J Gastroenterol 2008, 14:3301-3305.
128. Ben Ari Z., Mehta A., Lennard L., Burroughs A.K. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995, 23:351-354.
129. Kaskas B.A., Louis E., Hindorf U., Schaeffeler E., Deflandre J., Graepler F., et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003, 52:140-142.
130. Czaja A.J., Carpenter H.A. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006, 51:968-975.
131. Wang K.K., Czaja A.J., Beaver S.J., Go V.L. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989, 10:39-43.
132. Richardson P.D., James P.D., Ryder S.D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000, 33:371-375.
133. Van Thiel D.H., Wright H., Carroll P., Abu-Elmagd K., Rodriguez-Rilo H., McMichael J., et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995, 90:771-776.
134. Fernandes N.F., Redeker A.G., Vierling J.M., Villamil F.G., Fong T.L. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999, 94:241-248.
135. Burak K.W., Urbanski S.J., Swain M.G. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998, 29:990-993.
136. Kanzler S., Gerken G., Dienes H.P., Meyer zum Buschenfelde K.H., Lohse A.W. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis-report of three cases. Z Gastroenterol 1997, 35:571-578.
137. Czaja A.J., Carpenter H.A., Lindor K.D. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999, 30:1381-1386.
138. Barth E., Clawson J. A case of autoimmune hepatitis treated with rituximab. Case Rep Gastroenterol 2010, 4:502-509.
139. Weiler-Normann C., Wiegard C., Schramm C., Lohse A.W. A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. Am J Gastroenterol 2009, 104:2877-2878.
140. Germano V., Picchianti Diamanti A., Baccano G., Natale E., Onetti Muda A., Priori R., et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005, 64:1519-1520.
141. Manns M.P., Woynarowski M., Kreisel W., Lurie Y., Rust C., Zuckerman E., et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010, 139:1198-1206.
142. Miyake Y., Iwasaki Y., Terada R., Onishi T., Okamoto R., Sakai N., et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006, 23:1347-1353.
143. Verma S., Gunuwan B., Mendler M., Govindrajan S., Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004, 99:1510-1516.
144. Mottershead M., Neuberger J. Transplantation in autoimmune liver diseases. World J Gastroenterol 2008, 14:3388-3395.
145. Liberal R., Longhi M.S., Grant C.R., Mieli-Vergani G., Vergani D. Autoimmune hepatitis after liver transplantation. Clin Gastroenterol Hepatol 2012, 10:346-353.
146. Kerkar N., Hadzic N., Davies E.T., Portmann B., Donaldson P.T., Rela M., et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998, 351:409-413.
147. Longhi M.S., Meda F., Wang P., Samyn M., Mieli-Vergani G., Vergani D., et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008, 47:581-591.
148. Gueguen M., Meunier-Rotival M., Bernard O., Alvarez F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 1988, 168:801-806.
149. Longhi M.S., Hussain M.J., Bogdanos D.P., Quaglia A., Mieli-Vergani G., Ma Y., et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007, 46:472-484.
150. Longhi M.S., Hussain M.J., Kwok W.W., Mieli-Vergani G., Ma Y., Vergani D. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 2011, 53:536-547.